Equities Analysts Offer Predictions for SLNO Q1 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Stock analysts at HC Wainwright decreased their Q1 2025 earnings estimates for Soleno Therapeutics in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.83) per share for the quarter, down from their previous estimate of ($0.71). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q2 2025 earnings at ($0.84) EPS, Q3 2025 earnings at ($0.84) EPS, Q4 2025 earnings at ($0.83) EPS and FY2025 earnings at ($3.34) EPS.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.41).

SLNO has been the subject of a number of other reports. Lifesci Capital upgraded shares of Soleno Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 4th. Robert W. Baird reiterated an “outperform” rating and issued a $72.00 price target on shares of Soleno Therapeutics in a research note on Monday, December 2nd. Finally, Stifel Nicolaus began coverage on shares of Soleno Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $74.00 price target for the company. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Soleno Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $71.20.

Soleno Therapeutics Stock Down 0.1 %

Shares of SLNO stock opened at $44.94 on Thursday. The company has a 50 day moving average price of $47.16 and a 200-day moving average price of $49.83. Soleno Therapeutics has a 52 week low of $36.61 and a 52 week high of $60.92. The firm has a market capitalization of $1.94 billion, a PE ratio of -13.54 and a beta of -1.46.

Insider Activity at Soleno Therapeutics

In other Soleno Therapeutics news, CEO Bhatnagar Anish sold 10,937 shares of Soleno Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total transaction of $496,649.17. Following the transaction, the chief executive officer now owns 708,616 shares of the company’s stock, valued at $32,178,252.56. The trade was a 1.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kristen Yen sold 2,340 shares of Soleno Therapeutics stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $46.18, for a total transaction of $108,061.20. Following the transaction, the insider now directly owns 76,605 shares in the company, valued at $3,537,618.90. This represents a 2.96 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,360 shares of company stock worth $790,119. 12.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Soleno Therapeutics

Several hedge funds have recently modified their holdings of the stock. Polar Asset Management Partners Inc. lifted its holdings in shares of Soleno Therapeutics by 296.8% in the fourth quarter. Polar Asset Management Partners Inc. now owns 125,400 shares of the company’s stock worth $5,637,000 after buying an additional 93,800 shares in the last quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new position in shares of Soleno Therapeutics in the fourth quarter worth $13,451,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Soleno Therapeutics by 24.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 27,504 shares of the company’s stock worth $1,236,000 after buying an additional 5,462 shares in the last quarter. Union Square Park Capital Management LLC purchased a new position in shares of Soleno Therapeutics in the fourth quarter worth $2,248,000. Finally, Vestal Point Capital LP lifted its holdings in shares of Soleno Therapeutics by 47.2% in the fourth quarter. Vestal Point Capital LP now owns 1,060,000 shares of the company’s stock worth $47,647,000 after buying an additional 340,000 shares in the last quarter. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.